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We present an integrated approach that predicts and validates novel anti-cancer drug targets. We first built a classifier
that integrates a variety of genomic and systematic datasets to prioritize drug targets specific for breast, pancreatic
and ovarian cancer. We then devised strategies to inhibit these anti-cancer drug targets and selected a set of targets
that are amenable to inhibition by small molecules, antibodies and synthetic peptides. We validated the predicted drug
targets by showing strong anti-proliferative effects of both synthetic peptide and small molecule inhibitors against our
predicted targets.Background
Treatment options for a variety of deadly cancers remain
limited and the productivity of existing drug develop-
ment pipelines, despite years of biomedical research, has
been steadily declining. This is partly because current
drug discovery efforts are mainly focusing on previously
validated 'druggable' protein families such as kinases [1].
This leaves a vast space of the protein universe unex-
ploited by cancer drugs. Hence, there is an urgent need for
the identification and validation of new cancer-relevant
targets. Fortunately, the emergence of high-throughput
techniques, such as short hairpin RNA (shRNA) screening
[2], transcriptional profiling [3], DNA copy number detec-
tion [4] and deep sequencing [5], has led to substantial ad-
vances in our understanding of human cancer biology.
While the wealth of information in these datasets presents
an opportunity to leverage these for finding novel drug
targets, it remains a challenge to systematically integrate
all these highly heterogeneous sources of information to
identify novel anti-cancer drug targets. Several previous
studies have analyzed a few different biological aspects in
cancers with the purpose of cancer gene identification.* Correspondence: pi@kimlab.org
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unless otherwise stated.For instance, one group found that genes whose expres-
sion and DNA copy number are increased in cancer are
involved in core cancer pathways [6,7], while another
showed that cancer drivers tend to have correlations of
somatic mutation frequency and expression level [8,9].
Moreover, past studies that combined large-scale datasets
have mainly focused on the simple characterization of
cancer-related genes without any venue to inhibit and
validate these targets [10,11]. Therefore, it is essential
to develop a novel computational approach that can ef-
fectively integrate all available large-scale datasets and
prioritize potential anti-cancer drug targets. Furthermore,
while such predictions are useful, it is of crucial import-
ance to experimentally validate them. A straightforward
way for validation is to generate inhibitors to such targets
and test them in model systems.
Overall, there exist roughly three broad ways to generate
an inhibitor (and lead compound for drug development)
to a given target protein. First, small molecules comprise
the major class of pharmaceutical drugs and can act either
on intra- or extra-cellular targets blocking receptor signal-
ing and interfering with downstream intracellular mole-
cules. The classic approach to find a novel small molecule
is to screen very large chemical libraries. An alternative
route is to find new therapeutic indications of currently
available drugs (drug repositioning). Several studies have
assessed potential anti-cancer properties of existing drugsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treatment of non-cancer diseases [12]. Recently, system
biology approaches have been intensively applied to dis-
cover novel effects for existing drugs by analyzing large
data sets such as gene expression profiles [13], side-effect
similarity [14] and disease-drug networks [15]. In particu-
lar, sequence and structural similarities among drug tar-
gets have been successfully utilized to find new clinical
indications of existing drugs [16]. Second, antibodies that
interfere with an extracellular target protein have shown
great efficacy, such as altering growth signals and blood
vessel formation of cancer cells. Recently developed tech-
nologies, such as hybridoma or phage-display, have led to
the efficient generation of antibodies against given targets
[17]. Finally, synthetic peptides are a promising class of
drug candidates. Their properties lie between antibodies
and small molecules, and there have been numerous efforts
to create peptides that can affect intracellular targets
[18,19]. As with antibodies, several approaches to systemat-
ically generate inhibitory peptides have been developed
[20]. A successful approach for drug target prediction and
validation needs to include both a method to generate a list
of target candidates and a systematic approach to validate
targets using one or more of the ways described above.
Here, we developed a computational framework that
integrates various types of high-throughput data for
genome-wide identification of therapeutic targets of
cancers. We systematically analyzed these targets for
possible inhibition strategies and validate a subset by
generating and testing inhibitors. Specially, we identi-
fied novel targets that are specific for breast (BrCa),
pancreatic (PaCa) and ovarian (OvCa) cancers, which
are major sources of mortality throughout the world. By
analyzing the relevance of sequence, functional and net-
work topological features, we prioritized a set of pro-
teins according to their probability of being suitable
cancer drug targets. We also examined each target for
potential inhibition strategies with small molecules,
antibodies and synthetic peptides. For the case of small
molecules, we further identified several compounds
already approved as drugs for different clinical indica-
tions; these drugs are ideal candidates for trials as po-
tential novel anti-cancer agents. To validate a subset of
targets, we used phage display to generate high-affinity
peptide inhibitors against our predicted targets and
showed their biological effects in cancer cells. Furthermore,
we validated additional targets using high-throughput
chemical library screening, proving potential efficacy
of small molecule inhibitors against our predicted targets.
Methods
Biological and network-topological signatures
We examined 13 biological and network-topological prop-
erties of cancer drug targets (Additional file 1). Geneessentiality data were obtained from large-scale shRNA
screening against 29 BrCa, 28 PaCa and 15 OvCa cell lines
[2]. To examine gene essentiality, we used average GARP
(Gene Activity Ranking Profile) score across cell lines cor-
responding to their cancer type. We compiled mRNA ex-
pression data and DNA copy number profiles from the
Cancer Cell Line Encyclopedia (CCLE) [21]. CCLE con-
tains the information of 58 breast, 44 pancreatic and 50
ovarian cancer cell lines. Similar to gene essentiality, we
examined average robust multi-array average (RMA)-gen-
erated gene expression values and average DNA copy
number depending on cancer types. In addition, we mea-
sured how many times genomic properties of known can-
cer drug targets are altered in tested cancer samples (for
example, significantly essentialized, over-expressed, and
highly amplified). On average, all genomic signatures of
known cancer drug targets were significantly altered in
20% of cancer samples; meanwhile, putative non-drug tar-
gets showed the alterations in less than 8% of samples
(Additional file 2). We considered that a gene is altered if
its genomic signature value (for example, essentiality,
mRNA expression, and DNA copy number) is ranked
within the top 10% of all genomic signature values in a
given cancer sample.
Mutation data were downloaded from the COSMIC
database [22]. We counted the number of all observed
mutations in DNA sequence to decide mutation occur-
rence of each gene-product. Position enrichment is the
maximum number of mutations that are observed at
the specific position of one gene product. We measured
the ratio of the number of non-synonymous mutations
to the number of synonymous mutations (dN/dS ratio).
Since each protein has a different size (coding sequence
length) and different number of mutations, we normal-
ized mutation occurrence (number of mutations in a
gene) by coding sequence length for the fair comparison
of the mutational property of proteins. Position enrich-
ment is measured using this normalized mutation occur-
rence. To assess whether mutation information of the
COSMIC database is biased to a set of specific genes
that are frequently studied, we calculated mutation oc-
currence of each gene product using an independent set
of whole-genome sequencing data [6,23-26]. We com-
pared the number of mutations observed from the COS-
MIC database with those from whole-genome sequencing
data and found that there is a positive correlation between
two datasets, indicating that COSMIC data contain reli-
able mutation information (Additional file 3). In the case
of BrCa, we considered all reported mutations in BrCa in-
stead of considering subtype-specific mutations.
The human interactome was built on a network of
integrated global protein-protein interactions [27]. All
network-topological features were calculated by the Py-
thon package NetworkX [28]. Briefly, degree is defined
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of the fraction of all the shortest paths that pass through
the gene. Closeness centrality is a reciprocal of average
distance to all other nodes from the gene. Clustering co-
efficient is the fraction of possible triangles that exist.
Predicting targets for cancer drugs
Generating datasets
Cancer drugs, including approved drugs and clinical trial
drugs, were collected from NCI data files [29] and the
Therapeutic Target Database, which is a richly annotated
database of drugs, drug targets and their clinical indications
[30]. We selected drugs that are used for the treatment of
BrCa, PaCa, and OvCa. After collecting anti-BrCa, -PaCa
and -OvCa drugs, their targets were identified from Drug-
Bank [31] and the Therapeutic Target Database. In total,
62 known BrCa drug targets, 69 known PaCa targets and
known 45 OvCa targets constituted the positive dataset.
Putative non-drug targets (negative set) are defined as
proteins that (1) are non-existent or absent from the
DrugBank and Therapeutic Target Database, (2) are not
annotated as cancer-associated proteins, (3) do not physic-
ally interact with known cancer drug targets, and (4) do
not share Pfam functional domains [32] and sequence
similarity (<30% of sequence identity) with known cancer
drug targets. We removed the cancer-associated proteins
from the negative set in order to obtain the best possible
series of non-drug targets for cancer treatment. To collect
cancer-associated proteins, we used a text-mining method
and examined experimental applications of 15,663 human
proteins to cancer studies based on the pre-existing litera-
ture on cancer pathogenesis. In total, 5,169 proteins were
considered as putative non-drug targets (Additional file 4).
Machine learning and feature selection
Support vector machines (SVM) with radial basis func-
tion (RBF) kernels (software available at [33]) were used
to classify proteins into two classes: cancer drug targets
and non-cancer drug targets. SVMs are a widely used
supervised learning algorithm with excellent perform-
ance on many applications in cancer biomarker identifi-
cation [34], inferring gene-disease association [35] and
drug target identification [36]. SVMs are particularly at-
tractive in the application of genome-wide identification
of anti-cancer drug targets since they can handle both
large and noisy datasets and are robust to over-training.
Studies that compared several multivariate methods
showed that SVMs provide the most accurate model to
the training set, allowing the reliable classification of
data sets [37].
After collecting 13 biological and network-topological
features (Additional file 1), we identified the most rele-
vant features using the SVM-recursive feature elimin-
ation (SVM-REF) method [38]. Some features correlatedwith each other; for example, the number of interacting
partners of a given node (degree) generally shows a positive
correlation with the number of shortest paths that pass
through a given node (betweenness) in protein-protein
interaction (PPI) networks [39]. SVM-REF removes such
redundant features generalizing performance and provides
the ranking of each feature on all the training set.
SVM-REF implements backward feature elimination
and searches an optimal subset of features. First, SVM-
REF trains the SVM on the data set with all tested fea-
tures. Next, tested features are ranked according to the
weight vector of the SVM and the least important fea-
ture is identified and removed according to a ranking
criterion. The process repeats with the remaining fea-
tures until SVM-REF achieves the highest accuracy of
classification. Finally, SVM-REF provides the ranking
of each feature. We selected the best five features that
represent each biological and network-topological prop-
erty. The highest scoring features are GARP score for gene
essentiality, RMA intensity for mRNA expression, row
chromosomal copy number for DNA copy number, muta-
tion occurrence for somatic mutation pattern and close-
ness centrality for network-topological property. These
selected relevant features are used to build the final opti-
mized classifiers that distinguish cancer drug targets from
other proteins.
To select the best prediction model after selecting the
optimal set of features, 10-fold cross-validation was con-
ducted on a training set composed of known BrCa, PaCa
and OvCa drug targets as a positive set and putative
non-drug targets as a negative set. We used a grid search
to find the best combination of model parameters (C, γ
and weights for cancer drug targets and putative non-
drug targets) for the SVM-RBF kernel. Since the size of
the positive dataset (known drug targets) is smaller com-
pared to the size of the negative dataset (putative non-
drug targets), the learning weight of the positive dataset is
increased in order to create a balanced dataset. We intro-
duced an error penalty parameter to ensure generalization
of the classifier. The ratio of the error penalty for known
drug targets:putative non-drug targets is set to 100:1 and
applied in the SVM program using the weight parameter
(Wi) for both classes (positive targets and negative non-
targets). The benchmark study that compared several
methods to deal with unbalanced data sets showed that
assigning a penalty value (Wi) outperforms alternative
methods, including generation of pseudo-positive samples
and re-sampling (random selection of a few negative sam-
ples) [40]. Various pairs of parameters (C, γ and Wi for
drug targets and non-drug targets) are evaluated and the
one with the best cross-validation accuracy is picked. After
selecting the best model parameters, the whole training
set is trained again to generate the final classifier. The
optimal parameters of cancer-specific classifiers and
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procedures to optimize the final prediction model (SVM-
REF and grid-search) have different roles in generating
final predictors and are performed separately. Thus, there
is no effect and influence of one procedure on the other
though they show a synergistic effect when combined.
Target classification according to therapeutic classes
Identified drug targets are divided into three groups de-
pending on their therapeutic class; antibodies, synthetic
peptides or small molecules. To do this, we examined the
structural properties and cellular localizations of predicted
targets. UniProt subcellular localization annotations were
used to assign cellular localization to the predicted targets
[41]. For the identification of antibody targets, we selected
secreted proteins and membrane proteins that have extra-
cellular domains based on the notion that antibodies gen-
erally recognize protein fragments in the extracellular
space [42]. To examine whether membrane proteins have
extracellular domains, we used the topological informa-
tion of membrane proteins that have been deposited in
Uniprot. If membrane proteins have extracellular frag-
ments longer than 40 amino acids, we considered them as
extracellular domains. Targets for synthetic peptides were
selected if proteins have known peptide-binding domains
and localize at the cytoplasm and/or nucleus based on the
notion that peptides can penetrate lipid bilayer. The PepX
database was used to determine a list of known peptide-
binding domains derived from protein fragments or protein
domains in complex with peptides [43]. To characterize tar-
gets for small molecules, we selected targets for which
small molecules have been characterized and used for
clinical applications. We used the ChEMBL database (ver-
sion 15) [44], from which we extracted compounds that
are characterized as inhibitors or antagonists of our pre-
dicted targets as well as approved and experimental drugs.
We considered targets if their STITCH score is more than
0.7. The STITCH database compiles chemical-protein in-
teractions curated by text-mining of the literature and
provides confidence scores that reflect the level of signifi-
cance and certainty of interaction between small mole-
cules and targets. A STITCH score of 0.7 is generally used
as a cutoff to define high-confidence interactions [45,46].
To find more reliable targets of small molecules, we se-
lected targets that are already known targets of approved
and experimental drugs in the DrugBank and Therapeutic
Target Database. These drugs and targets were considered
as repositioned drugs and repositioned targets, respectively.
Computational evaluation of predicted drug targets
First, we assessed how many predicted targets are related
to cancer pathogenesis. To do this, we collected cancer-
related proteins whose functional alterations are causally
implicated in oncogenesis (for example, oncogene products,tumor-suppressor gene products and proteins in core can-
cer pathways). We identified 1,367 cancer-related proteins,
compiled from CancerGenes [47] using the queries 'onco-
gene' and 'tumor suppressor' [48] and two consensus stud-
ies [49,50]. To identify cancer disease gene products, we
used the Online Mendelian Inheritance in Man (OMIM)
database, which contains the most complete known
disease-gene associations [51]; this revealed 27 BrCa-, 10
PaCa- and 14 OvCa-related genes. Second, we investigated
the experimental applications of bioactive small molecules
(inhibitors and antagonists) of predicted targets based on
the assumption that if predicted targets are associated
with cancer pathogenesis, their bioactive molecules would
be applied to cancer research. Using text-mining, we ex-
amined whether predicted targets and 'cancer' are com-
monly observed as keywords in the title and/or abstract of
literature deposited in NCBI's PubMed database. Third,
we examined the shortest path length between predicted
targets and cancer disease gene products. The shortest
path length for integrated global protein-protein inter-
actions [27] was calculated using the Python package
networkX.
Experimental evaluation of predicted targets using
peptide inhibitors
Target selection
To select targets of peptide inhibitors, we manually exam-
ined if predicted targets have peptide-binding domains
that have relevance to cancer. We selected PPWD1 and
NXF1 since they have well-characterized peptide domains
(WD40 domain for PPWD1 and LRR domain for NXF1),
and these domains have critical roles in cancer pathogen-
esis. The WD40 domain mediates signal transduction and
transcriptional regulation during the cell cycle and apop-
tosis [52]. The LRR domain mediates specific binding to
constitutive transport element (CTE) RNA and metabol-
ism of various post-transcriptional mRNAs that regulate
cancer cell proliferation and transformation [53,54].
Though PPWD1 and NXF1 have functional relevance in
cancer pathogenesis and potential to be reliable drug tar-
gets, both proteins have not been used as targets for pep-
tide and small molecule drug design. Based on these
observations, we decided to generate peptide inhibitors of
PPWD1 and NXF1.
Cloning and protein expression
For cloning target domains, the PPWD1-WD40 domain
and NXF1-LRR domain boundaries were defined as the
union of the domain regions identified by Pfam [32],
SMART [55], and Gene3D [56]. DNA fragments encod-
ing the identified domains were synthesized (GenScript
Inc., Piscataway, NJ, USA) and cloned into a vector de-
signed for the expression and purification of domains fused
to the carboxyl terminus of glutathione S-transferase
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structs were verified by DNA sequencing.Selection of peptide library
A random hexadecapeptide library (X16, where X is any
amino acid) was fused to the N-terminus of the gene -8
major coat protein of M13 filamentous phage. The phage
displayed peptide library (>1010 unique members) was
used to select peptide binders for the collection of purified
GST-target domain fusion proteins. High-throughput
phage display selections were carried out as described
previously [57]. In short, five rounds of phage selec-
tions, including absorption, washing, elution and amp-
lification, were conducted to enrich the bound phage
for each domain. We isolated individual clones from
the phage pools to test for positive interactions with
the cognate target domains by phage ELISA as described
[58]. In total, 44 clones with an ELISA protein/GST signal
above 3 were sequenced, resulting in the isolation of 4
unique peptide sequences for PPWD1-WD40 domain and
11 for NXF1-LRR domain, which were manually aligned
by an expert. The sequence with the highest ELISA signal
was selected for cell viability assays.Lentiviral vector preparation
Sense and antisense oligonucleotides containing peptide
sequences were obtained from Sigma (Oakville, Ontario,
Canada). Oligonucleotide pairs were annealed at 55°C and
extended by PCR using Accuprime pfx DNA polymerase
(Invitrogen, Burlington, ON, Canada) at a concentration
of 1 μM in a volume of 50 μl. PCR reactions were done in
a thermal cycler (Biorad, Mississauga, Ontario, Canada).
The peptide sequences in the PCR products were intro-
duced in pLJM1 plasmid containing a green fluorescent
protein (GFP) sequence at the N-terminus. The PCR frag-
ments containing the peptide sequences and the pLJM1
plasmid (5 μg) were doubly digested by EcoRI (New
England Biolabs, Whitby, Ontario, Canada) and XmaI
(New England Biolabs) for 4 to 6 h. DNA fragments were
then separated using a 1% agarose gel. The vector and
insert bands were excised and DNA was extracted using
Qiaquick gel extraction kit (QIAGEN, Valencia, CA, USA).
DNA was eluted with TE buffer. Ligation was performed
in 20 μl reaction volume using 400 units of T4 DNA ligase
(New England Biolabs) with 2 μl of PCR fragments and 15
to 20 ng of prepped vector for overnight at 16°C. Ligation
mixture (2 μl) was used to transform 25 μl Max Efficiency
DH5™ T1 Phage-resistant Competent Cells (Invitrogen),
following the manufacturer’s heat shock protocol. The
transformed cells were recovered in 200 μl of super op-
timal broth with catabolite repression (SOC) for 1 h at
37°C and plated on agar plates.Lentiviral production
Lentiviruses were made by transfecting packaging cells
(293 T) with a three-plasmid system as previously de-
scribed [59,60]. Transfections were performed in six-well
plates at a density of 2.5 × 105 cells per well in 2 ml
media (Dulbecco's modified Eagle's medium (DMEM)/
10% inactivated fetal bovine serum (IFS)/no antibiotics)
24 h before transfection and grown at 37°C in 5% CO2.
DNA for transfections was prepared by mixing 900 ng
pCMV-dR8.74psPAX2 and 100 ng pMD2.G with 1 μg
peptide expressing plasmids in each well. A mixture of
96 μl OptiMEM (Gibco, Burlington, ON, Canada) and
6 μl FUGENE (Roche, Mississauga, ON, Canada) was
then added to the DNA and this mixture was incubated
for 15 minutes before addition to the packaging cells. Cells
were incubated for 24 h, and the medium was changed to
remove remaining transfection reagent. Lentiviral super-
natants were collected at 48 and 72 h post-transfection.
Lentiviruses were frozen at -20°C or -80°C for long-term
storage.
Cell infection and cell viability assay
RWP1 cells were seeded at a density of 5,000 cells per
well in 96-well plates in a final volume of 100 μl of culture
medium per well. Cells were infected with lentiviruses ex-
pressing the desired constructs at different multiplicity of
infection (MOI) values. To determine the MOI values, we
measured the proportion of cells that acquire resistance to
puromycin treatment following infection, as described
previously. Polybrene (5 μg/ml) was added to the cell
medium. Cells were incubated overnight in a humidified
incubator at 37°C in 5% CO2. On the next day, the
medium was replaced with fresh medium. Cells were in-
cubated at 37°C for a period of 72 h in a humidified incu-
bator. To measure cell viability, 10 μl of AlamarBlue was
added to each well of a 96-well plate. After a 2 h incuba-
tion (37°C), fluorescence intensity was measured using
PHERAstar SpectraMax Plus384 microplate reader (BMG
LABTECH, Cary, NC, USA) with an excitation filter of
535 nm and an emission filter of 590 nm.
Screening of chemical compounds against predicted drug
targets
Cell lines and reagents
Panc0813 cells were maintained in RPM1 (ATCC) and
cultured at 37°C in 5% CO2 in their recommended
medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin/glutamine. AlamarBlue reagent
was purchased from Invitrogen.
High-throughput chemical compound screening
We performed high-throughput chemical library screen-
ing for the experimental evaluation of predicted drug
targets. The TocRis chemical Library® (TocRis Chemical,
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biologically and pharmacologically established chemicals,
including a variety of marketed drugs, was obtained
from several vendors and purposely assembled by the
SMART Laboratory and the Ontario Institute for Cancer
Research to specifically target molecular entities associ-
ated with signaling pathways, cellular processes and dis-
parate metabolic events. Next, these chemical libraries
were applied to Panc0813 pancreatic cancer cells. Tar-
gets of 1,580 small molecules were determined using the
STITCH [46] and ChEMBL databases [44]. We selected
targets if they have a high STITCH confidence score
(>0.7) against given small molecules and considered
small molecules if they are reported as inhibitors or an-
tagonists of given targets using the ChEMBL database.
The Beckman BioMek FX and the Samuel Lunenfeld Re-
search Institute High-Throughput Screening Robotics
platform were applied for cell seeding, treatment and
viability assessment. Panc0813 cells were seeded to 384-
well culture plates (Corning, Corning, NY, USA) at a
density of 600 cells/well and incubated for 24 h. Com-
pounds were added to a concentration of 1 μM. Cells
treated with 0.1% dimethyl sulfoxide (DMSO) vehicle
alone were used as the negative controls, while media
only was used to determine the assay noise. To measure
cell viability, 10 μl of AlamarBlue was added to each well
after a 72 h incubation with chemical compounds. After
a 2 h incubation (37°C), fluorescence intensity was measured
using PHERAstar microplate reader (BMG LABTECH) with
an excitation filter of 535 nm and an emission filter of
590 nm. To get dose-dependent response curves of
eight PaCa inhibitors and two non-PaCa inhibitors,
stock solutions of kinase inhibitors (Dasatinib, BI-2536
and BMS-536924; 1 mg/ml) and other small molecule
inhibitors (A-205804, ACDPP hydrochloride, rolipram,
loperamide, yohimbine, D4476 and 2-hydroxysaclogen;
5 mg/ml) were prepared in DMSO and serially diluted
two-fold in the same solvent. Aliquots (0.2 μl) from a
series of dilutions (10 dilutions) were added to a plate.
Cell viability was measured after a 72 h incubation with
small molecule inhibitors. Each small molecule concen-
tration was presented in duplicate.
Results
Systematic genomics analysis of existing drug targets
We devised a systematic pipeline that integrates various
biological properties and identifies novel potential anti-
cancer drug targets (Figure 1A). First, we collected
genome-level datasets representing a wealth of informa-
tion about human cancers, including gene essentiality,
mRNA expression, DNA copy number alteration, som-
atic mutation patterns as well as PPI network data. We
then systematically analyzed how much these genomicand systems properties can distinguish drug targets from
other proteins. Next, we generated three cancer type-
specific classifiers to characterize targets that have func-
tional relevance in given cancers.
To build a classifier, we first needed to generate a gold
standard set. To this end, we generated a positive set
(known targets of approved and clinically tested anti-
cancer drugs, which are specific to cancer types) by
extracting 62, 69 and 45 drug targets for BrCa, PaCa and
OvCa. As a negative set, we generated a list of 5,169 pu-
tative non-drug targets by focusing on proteins that are
not currently drug targets and that are not associated
with cancer pathogenesis (for details see Methods and
Additional file 4). We found that cancer drug targets
possessed particular genomic signatures specific to the
given cancer type. First, drug targets tend to be specific-
ally essential in the given cancer types. The essentialities
of BrCa, PaCa and OvCa drug targets (indicating lethal-
ity in response to shRNA-mediated knockdown in cell
lines derived from this particular cancer type) are 3.88,
3.04 and 3.64 times higher, respectively, than those of
putative non-drug targets in the given cancer types
(average P-value = 1.62 × 10-18; Figure 1B). In mRNA ex-
pression studies in cancer cell lines, drug targets also
show significantly higher expression levels in the given
cancer type compared with putative non-drug targets
(average P-value = 2.17 × 10-11; Figure 1C). Moreover, the
likelihood of being a drug target increases consistently
with increasing gene essentiality and mRNA expression
(Additional file 6). Similar to gene essentiality and mRNA
expression, drug targets have higher DNA copy num-
ber in given cancer types (average P-value = 1.08 × 10-5;
Figure 1D) and are likely to be localized in the amplified
region (copy number >2.5) in chromosomes compared to
putative non-drug targets (Additional file 6).
We also found that cancer drug targets have unique
somatic mutation patterns. Drug targets are mutated
more frequently in the given cancer compared to puta-
tive non-drug targets (Figure 1E). In BrCa, on average,
there were 3.32 mutations per BrCa drug target, while
there were 0.37 mutations in a putative non-drug target.
Likewise, mutation occurrences of PaCa and OvCa drug
targets are 2.05 and 9.99 times higher than those of pu-
tative non-drug targets. Also, drug targets show signs of
selection; we measured the ratio of the number of non-
synonymous mutations to the number of synonymous
mutations (dN/dS ratio) and found that drug targets
showed significantly higher dN/dS ratios than putative
non-drug targets in all cancer types (Figure 1F). More-
over, there is a significant clustering of mutations in spe-
cific amino acid positions in drug targets (Figure 1G),
consistent with the fact that specific positions in drug
targets act as drivers and play important roles in cancer
pathogenesis [61].
Figure 1 Biological properties of drug targets. Genomic signatures of drug targets for breast cancer (BrCa), pancreatic cancer (PaCa) and
ovarian cancer (OvCa) are shown. (A) Overview of the systematic pipeline to identify and validate novel anti-cancer drug targets. (B) Gene essentiality,
(C) mRNA expression, (D) DNA copy number, (E) mutation occurrence, (F) mutation pattern and (G) position enrichment of known cancer drug targets
(black bars) and putative non-drug targets (gray bars) are compared. Error bars indicate standard deviation of drug targets.
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text of other proteins, we examined network positions of
cancer drug targets in a global human PPI network.
Drug targets are located at the center of the network;
they show significantly higher degree, betweenness and
closeness centrality (P-value < 10-7) and have lower clus-
tering coefficients compared with the non-drug targets
(average P-value = 1.16 × 10-3; Additional file 7). We ob-
served similar network properties of drug targets when
we used a different type of PPI network derived from
the high-throughput yeast two-hybrid screens [62,63]
(Additional file 8). Taken together, unique genomic and
network topological properties of known cancer drug
targets allow for distinguishing novel cancer drug targets
from other proteins. We hence sought to integrate thedifferentiating power of these features to extract an opti-
mized priority list of drug targets for each of the three
cancer types.
Predicting novel cancer drug targets
We then adopted a machine learning algorithm to inte-
grate the above features into a unified classifier that can
distinguish potential drug targets specific to cancer type
from other proteins. Based on the notion that choosing
a relevant subset of the original features avoids overfit-
ting and leads to better performance in machine learning
[64], we evaluated these genomic and network topo-
logical properties as input features for machine learning
and selected the most relevant features using a SVM-
REF method [38] (see Methods and Additional file 1).
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score), mRNA expression intensity (RMA score), DNA
copy number, mutation occurrence and closeness central-
ity in the PPI network. Using these features and an SVM
algorithm with a RBF kernel, we generated three classifiers
that can predict potential drug targets specific to BrCa,
PaCa and OvCa. From 10-fold cross-validation on the data
sets (known BrCa, PaCa and OvCa drug targets as a posi-
tive set and putative non-drug targets as a negative set),
we correctly assigned 55 of 62 BrCa drug targets (88.71%
sensitivity), 43 of 69 PaCa drug targets (62.32% sensitivity)
and 29 of 45 OvCa drug targets (64.44% sensitivity). Over-
all, the three classifiers showed an accuracy of 91.69% and
a specificity of 91.91% (Table 1). Next, we evaluated indi-
vidual features in terms of their discriminative power by
measuring the area under the receiver operating charac-
teristic curve (AUC) and found that our integrated ap-
proach far outperformed all single features (Figure 2A;
Additional file 9). The average performance of our clas-
sifiers (AUC) is 0.78. Meanwhile, on average, single
feature-based approaches achieve an AUC of 0.61. For
a more comprehensive evaluation, we compared the
precision-recall characteristics of our approach with
those of single feature-based predictions. The areas
under the precision-recall curves (AUCPRs) of our
classifiers are 4 to 15 times higher than AUCPRs of
single-based predictions (Additional file 9).
Finally, to predict cancer drug targets on a genome-wide
scale, we applied our optimized classifiers to 15,663 hu-
man proteins and measured the probability of each to be a
suitable drug target specific to cancer types. We consid-
ered all putative cancer drug targets that are within the
top 5% of our probability scores. At this cutoff, predicted
cancer drug targets showed low false-positive rates ran-
ging from 1.41% to 2.20% depending on cancer types
(Additional file 10). Of the predicted drug targets, 122 are
global-cancer targets that are observed in all cancer types
and 266, 462 and 355 are specific to BrCa, PaCa and
OvCa, respectively (Figure 2B; Additional file 11). Our
scores represent a prioritization of potential cancer drug
targets, which is representative of their importance in can-
cer as measured by the various features we integrated. Of
course, it is in itself not yet an identification of real drug
targets, but more to be understood as a guideline.
Whether there is a potential venue for inhibition (that is,
some measure of 'druggability') is investigated below.Table 1 Performance evaluation of classifiers
Classifier ACC Sensitivity Specificity BACa AUC
BrCa 93.33 88.71 93.38 91.05 78.46
PaCa 89.65 62.32 90.02 76.17 77.47
OvCa 92.08 64.44 92.32 78.38 79.31
aBAC is balanced accuracy, which is defined as the arithmetic mean of
sensitivity and specificity.To evaluate the reliability of our prediction results, we
compared our predictions with two other approaches
that used different methods to identify anti-cancer drug
targets. For the identification of drug targets, one ap-
proach modeled metabolic networks [65] and the other
studies identified target candidates that have negative
genetic interactions [66]. We found that a total of 22.1%
of targets from the two approaches overlap with our pre-
dictions (Additional file 12A), while there is no overlap
between the predictions of the two approaches. Also, we
compiled a list of known drug targets (116 targets) of
very well-studied anti-cancer drugs using a cancer drug
resistance database (CancerDR) [67]. Our predictions
overlap significantly with these known anti-cancer drug
targets (P-value = 8.29 × 10-54; Additional file 12B). About
60% of known anti-cancer drug targets (69 targets) are
predicted as drug targets. Meanwhile, only two predicted
targets from the other approaches overlap with these
known anti-cancer targets (P-value >0.5). Furthermore,
when we relax the score cutoff, 95% of the known anti-
cancer drug targets (110 targets) are ranked within the top
30% of probability scores, suggesting that our probability
score is reliable to identify potential anti-cancer drug tar-
gets (Additional file 12C).
Properties of putative drug targets
With the list of putative targets at hand, we investigated
their biological and cellular properties and evaluated their
reliability using several genome- and network-wide ana-
lyses. First, we assessed whether predicted cancer drug
targets are enriched with cancer-related proteins (for ex-
ample, oncogene and tumor-suppressor gene products)
and cancer disease gene products (their genetic defects are
directly implicated in oncogenesis; see Methods). We ob-
served that predicted targets are significantly related to
cancer pathogenesis. As shown in Figure 2C, the chance
to find cancer-related proteins in the predicted targets
is about three times higher than in all human proteins
(P-values of all cancer types <1.00 × 10-5). Also, the chances
of predicted targets to be the products of cancer-disease
genes are 5.63 (BrCa), 2.77 (PaCa) and 4.37 (OvCa) times
higher than those of all human proteins (P-values of all
cancer types <1.00 × 10-5; Figure 2D). Next, we validated
the predicted targets based on the pre-existing literature
on cancer pathogenesis. Using a text-mining method,
we examined the experimental applications of bioactive
compounds (inhibitors or antagonists) and found that
compounds inhibiting our predicted targets are more
frequently used for cancer research compared to the com-
pounds of other human proteins (P-value = 1.90 × 10-3).
Bioactive compounds associated with 19.03% of drug tar-
gets (315 targets) have been applied to cancer research,
while 8.09% of human proteins and their compounds have
been used in cancer research (Figure 2E).
Figure 2 Performance evaluation of classifier and biological properties of predicted anti-cancer drug targets. (A) Receiver operating
characteristic (ROC) curve (left) and area under the ROC curve (AUC; right) of integrated approach and single dataset-based approaches are
compared. (B) Venn diagram of predicted drug targets for BrCa, PaCa and OvCa. (C,D) The possibility to find cancer-related proteins (C) and to
find cancer disease genes (D) in cancer drug targets (black) are compared with those possibilities of all human proteins (All, gray). (E) Analysis of
pre-existing literature dealing with cancer pathogenesis. The applications of bioactive compounds (inhibitors and antagonists) of cancer drug targets
(red) and all human proteins (All, gray) are compared. (F-H) Distributions of shortest path lengths of BrCa (F), PaCa (G) and OvCa (H). Shortest path
length between predicted cancer drug targets and cancer disease genes (red), between known cancer drug targets and cancer disease genes (green)
and between non-drug targets and cancer disease genes (gray) in a PPI network are shown. *P-value < 1.00 × 10-5.
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cancer drug targets and cancer disease gene products in
the human PPI network. We hypothesized that suitable
cancer drug targets are likely to be located close to dis-
ease gene products in the network [68]. Indeed, we ob-
served that predicted drug targets are significantly
closer to cancer disease gene products than other pro-
teins (P-values of all cancer types <1.00 × 10-5; red lines
in Figure 2F-H). In particular, the average shortest path
length between predicted targets and cancer diseasegene products is 2.84, which is similar to the shortest
path length between known drug targets and cancer
disease gene products (2.81). Meanwhile, the average
shortest path length between non-drug targets and dis-
ease gene products is 3.55 (the average shortest path
length of the entire network is 3.39). These results imply
that our classifier correctly captures potential anti-cancer
drug targets. Having a set of potential cancer drug target
candidates at hand, we sought to devise strategies to find
inhibitors to these molecules.
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We next investigated structural and cellular properties
of our predicted cancer drug target candidates to obtain
potential avenues for their inhibition (Figure 3A). We fo-
cused on three classes of potential cancer therapeutics,
namely antibodies, peptide-based compounds and small
molecules.
First, to define targets for antibodies, we searched for
targets that have extracellular domains and are thus
serum-accessible, as antibodies cannot traverse the cell
membrane (Figure 3A). We found a total of 257 poten-
tial antibody targets (Figure 3B; Additional file 11).
Among them, 30 are predicted to affect all cancer types,
whereas 28, 88 and 53 are specific to BrCa, PaCa and
OvCa, respectively. These antibody targets comprise
about 16% of predicted targets in each cancer type. We
found that antibodies against several of our predicted
targets have been shown to have efficacy in pre-clinical
settings. For example, antibodies against CD44 (BrCa
drug target), FLT3 (PaCa drug target) and EPHB2 (OvCa
drug target) reduce tumor cell invasion and engraftment
in cancer leading to antibody-dependent cell-mediated
cytotoxicity [69-71]. Also, immunotoxins against CD22Figure 3 Classification of predicted targets depending on therapeutic
on therapeutic classes. (B) Targets for antibodies. (C) Targets for synthetic p
overlap of therapeutic class-specific targets depending on cancer type and
predicted anti-cancer targets. (E) Identification of repositioned drugs and t
Administration (FDA)-approved drugs that have high specificity (number oand CD19, which are global cancer targets, showed their
effectiveness in eliminating acute lymphoblastic leukemia
cells [72]. These identified proteins could be targeted with
antibodies using established techniques such as hybrid-
oma or phage display [17].
Second, we identified 345 potential peptide targets that
have known peptide-binding domains and are thus tar-
getable with synthetic peptides. As extracellular targets
can be efficiently targeted using antibodies, we focused
here on intracellular targets (assuming that peptides can
be manipulated to cross the membrane [18,19]). On
average, 23.33% of predicted targets have these features
in each cancer type. Among them, 54, 70 and 56 are spe-
cific targets for BrCa, PaCa and OvCa (Figure 3C;
Additional file 11). It has been shown that synthetic
peptides binding to Zap70, Lck and Src (global cancer tar-
gets) block signaling downstream of these proteins and in-
duce apoptosis in cancer cells [73,74]. For validations, we
generated inhibitory peptides against a number of these
targets as potential drug leads and evaluated their efficacy
(see below).
Finally, for potential small molecule targets, we mined
extensive databases of existing small molecule inhibitorss classes. (A) Biochemical and cellular properties of targets depending
eptides. (D) Targets for small molecules. Venn diagrams show the
gray bars represent fraction of therapeutic class-specific targets in all
heir targets. (F) Overlap of repositioned targets of Food and Drug
f targets is less than five proteins).
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targets for which small molecules have been character-
ized and used for experimental studies (inhibitors and
antagonists) and clinical applications (approved and ex-
perimental drugs). We found that a total of 607 targets
can be inhibited by small molecules in a given cancer
(Figure 3D; Additional file 11). They comprise about
40% of predicted targets in each cancer type. Among
them, 86 (BrCa), 154 (PaCa) and 108 (OvCa) are cancer
type-specific targets. Indeed, we found that small mol-
ecule targets have functional relevance in specific cancer
pathogenesis. For instance, the inhibitors of aurora kin-
ase B (AURKB; a BrCa drug target) and serine/threonine
protein kinase Chk1 (CHEK1; a PaCa drug target) have
been shown to reduce cancer cell proliferation [75] and
induce DNA damage [76]. The inhibition of pituitary
tumor-transforming protein (PTTG1), an OvCa target,
restricts sister chromatic separation and tumorigenesis,
and thus has been studied as an important target for
ovarian cancer chemotherapy [77].
Of particular interest are small molecules that are
already approved as drugs. Associating alternative indica-
tions with approved drugs is a rapid way to find potential
cancer drug therapies (repositioned drugs) and target mol-
ecules (repositioned targets). To explore the repositioned
drugs and their targets, we searched for the subset of
small molecules that are already approved drugs and in-
hibit our predicted cancer drug targets (Figure 3E). We
found 85 repositioned targets that are inhibited by 224 US
Food and Drug Administration (FDA) -approved drugs
that have relatively high specificity (that is, that target less
than five proteins). Among the repositioned targets, 13
are global cancer targets while 8, 22 and 14 are specificFigure 4 Generation and biological evaluation of peptide binders again
(A) and NXF1-LRR domain (B) are selected based on the known domain-pep
and probability score (top and right). Structures of WD40 domain (Protein Da
High-affinity peptide binders against PPWD1-WD and NXF1-LRR and their
on the infection efficiency of lentiviruses are compared (bottom and right). Bo
as opposed to GFP control (Additional file 13). MOI represents multiplicity of itargets for BrCa, PaCa and OvCa, respectively (Figure 3F).
Furthermore, we identified additional potential targets
that are inhibited by approved compounds of lower speci-
ficity (see Additional file 13 for details). These targets
would be prime candidates for validation as inhibitory
small molecules are already available.
Generation of peptide inhibitors against predicted targets
We next sought to validate our methodology and assess
the feasibility of our targets. To this end, we generated
synthetic peptide inhibitors to two of our peptide bind-
ing PaCa targets: spliceosome-associated cyclophilin
(PPWD1) and Nuclear RNA export factor 1 (NXF1).
PPWD1 (WD40 domain) and NXF1 (LRR domain) have
well-characterized peptide binding domains that play
important roles in cancer pathogenesis (top and left
panels in Figure 4A,B; see Methods for details). PPWD1
and NXF1 have similar biological properties of known
drug targets in PaCa cell lines. They show high levels of
mRNA expression, gene essentiality, DNA copy number,
and closeness centrality in PPI networks resulting in
high probability scores to be reliable PaCa targets (top
and right panels in Figure 4A,B). Using peptide-phage
display, we successfully obtained peptide binders against
PPWD1-WD40 and NXF1-LRR (see Methods for details).
After five rounds of panning against PPWD1-WD40 and
NXF1-LRR, 44 clones were amplified and phage ELISA re-
vealed 4 unique peptide binders for PPWD1-WD40 and
11 for NXF1-LRR, which we can represent as a position
weight matrix (graphically as a Logo as in Figure 4A,B).
Identified PPWD1-WD40-binding peptides commonly
have the (G/A)P motif, while NXF1-LRR-binding peptides
have the GFEXLR motif (bottom and left panels inst predicted drug targets. (A,B) Peptide targets PPWD1-WD40 domain
tide structures (top and left) and genomic/network topological properties
ta Bank (PDB) ID: 1NEX) and LRR domain (PDB ID: 3P72) are shown.
sequence motifs are shown (bottom and left). Cell viabilities depending
th peptides show decrease in cell viability in a dose-dependent manner
nfection. *P-value <0.1.
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highest affinity signal (phage ELISA value) for further
studies; KVYTAPNRQDNYVIQN for PPWD1-WD40
and GFETLWARHAQGQTQV for NXF1-LRR.
Next, we evaluated the biological effects of the two pep-
tide binders in cells. To introduce peptide binders into
cells, we used a lentiviral delivery system, which is a power-
ful tool to deliver protein or peptide of interest to cells with
high transduction efficiency [78]. RWP1 PaCa cells, which
exhibit high mRNA expression levels of PPWD1 and
NXF1, were infected with peptide-expressing lentiviruses
(with the peptide fused on a GFP scaffold; see Methods for
details). We measured cell viabilities by changing the MOI
of lentivirus and found that peptide binders have suppres-
sive effects in PaCa cells. As shown in Figure 4 (bottom
and right panels), lentiviral infection reduced cell viability
in a dose-dependent manner, whereas a GFP control con-
struct resulted in no significant changes in cell viability
(Additional file 14). Lentivirus infection caused 30.11%
(PPWD1-WD40) and 31.22% (NXF1-LRR) reductions ofFigure 5 Screening of chemical compounds against predicted cancer
library against Panc0813 cells. (B) The fraction of compounds that lead to s
(cell viability ≥70%, right). Red bars indicate the inhibitors of PaCa targets;
targets or non-drug targets. (C) Cell viabilities after treatment with positive
molecule for pancreatic cancer treatment (orange), inhibitors of PaCa targe
considered as control (light gray). Asterisks indicate repositioned drugs.cell viability at the highest concentration (MOI = 1). These
results suggest that drugs based on these peptides could
be used as therapeutic agents for cancer therapy.
Validation of small molecule inhibitors to our drug
targets
We next sought to validate the identified small molecule
targets using high-throughput chemical library screens,
by measuring their effects on the viability of PaCa cells.
To this end, we selected two commercially available librar-
ies that contain 137 inhibitors of 113 PaCa targets and
1,206 compounds that inhibit other proteins (Figure 5A;
Additional file 15). To define reliable targets of inhibitors,
we only considered targets that have strong interactions
with inhibitors as derived from the STITCH database
(STITCH score > 0.7) [46]. We then measured the viability
of Panc0813 cells, a PaCa cell line, after treatment with
these libraries. We selected the Panc0813 cell line as it
shows relatively high expression levels of our targets, in-
cluding the target of dasatinib, our positive control. Whiledrug targets. (A) Procedure to screen high-throughput chemical
trong inhibition (cell viability <50%, left) and unchanged cell viability
gray bars indicate other tested compounds that inhibit non-PaCa
control, dasatanib, which is an experimentally/clinically studied small
ts (red) and other compounds (dark gray) are compared. DMSO is
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efficacy of the inhibitors of our targets, we do believe it
goes a long way to emphasize the strength of our method.
Our results showed that PaCa inhibitors exhibit strong
anti-cancer activity as treatment leads to significant reduc-
tion of Panc0813 cell viability compared to treatment with
other compounds (P-value = 2.64 × 10-3; Additional file 16).
As shown in Figure 5B, inhibitors of predicted PaCa tar-
gets were almost twice as likely to show strong inhib-
ition (reducing cell viability more than 50%, 17.52%
versus 9.87%; left panel of Figure 5B). Meanwhile, treat-
ment using the majority of other compounds (59.20%)
resulted in unchanged cell viability (cell viability ≥70%;
right panel of Figure 5B).
We especially focused on eight PaCa inhibitors that
have high specificities (number of binding proteins ≤5)
and that have been shown to efficiently inhibit our pre-
dicted targets (half maximal inhibitory concentrations
(IC50) ranging from 0.2 nM to 870 nM; Additional file 17).
The targets of these eight PaCa inhibitors show high
levels of mRNA expression, gene essentiality, DNA copy
number, and closeness centrality in PPI networks, result-
ing in high probability scores to be reliable PaCa targets
(Additional file 18). To evaluate the effect of PaCa inhibi-
tors on cell viability, we compared their effect on cell via-
bility with the effect of a negative set of other compounds.
To address the issue that many compounds have multiple
targets, we chose multiple sets with varying overlap in
their targets with the targets of our PaCa inhibitors.
We found that PaCa inhibitors reduced cell viability
significantly stronger than the negative set. The com-
pounds binding to none of the proteins that are bound
by PaCa inhibitors did not affect PaCa cell viability (cell
viability of 76.16%; the overall cell viability measured by
all screened compounds was 76.72%). Also, compounds
with limited overlapping sets of targets (share one to
three targets with PaCa inhibitors) showed similar levels
of cell viability (73.25% cell viability). Meanwhile, eight
PaCa inhibitors resulted in about 53% cell viability
(P-value <0.05; Additional file 19A). Furthermore, we
measured the statistical significance of cell viability
that is induced by a single PaCa inhibitor. All PaCa in-
hibitors reduced cell viability significantly (P-value <0.05;
Additional file 19B).
We found several studies that show the potential effica-
cies of PaCa inhibitors. For instance, BI-2536 inhibits
Polo-like kinase (PLK1; STITCH score = 0.973 and IC50 =
0.83 nM), a predicted PaCa target, and has shown anti-
proliferative potency against pancreatic adenocarcinoma
in both in vitro and in vivo studies [79]. BMS-536924,
which is an inhibitor of insulin-like grown factor-1 recep-
tor (IGF-1R; STITCH score = 0.987 and IC50 = 100 nM),
blocks cancer cell growth and mediates apoptosis [80]. In-
deed, treatment with BI-2536 and BMS-536924 showedsignificant loss of cell viability (cell viabilities of 37.77%
and 47.15%, respectively; Figure 5C) in cell line screens.
Meanwhile, treatment with other compounds (for ex-
ample, D4476, a CSNK1D inhibitor with STITCH
score = 0.084 and IC50 = 300 nM; and 2-hydroxysaclofen, a
GABBR1 inhibitor with STITCH score = 0.77 and IC50 =
11 μM) does not affect PaCa cell viability (90% cell viabil-
ity; dark gray bars in Figure 5C; Additional file 19B).
Importantly, we were able to validate three of the 'drug
repositioning' targets mentioned above (Figure 5C). We
observed reduced viability of Panc0813 cells in response
to treatments with several approved and experimental
drugs. For example, one FDA-approved anti-gastroenteritis
drug, loperamide, shows loss of cell viability (59.11%), pre-
sumably by targeting the voltage-gated calcium channel
subunit alpha-1A (CACNA1A; STITCH score = 0.82 and
IC50 = 870 nM). Yohimbine, which is an approved inhibitor
of adrenoceptor alpha 2A (ADRA2A; STITCH score =
0.997 and IC50 = 3.67 nM) and has been explored as a
therapeutic for impotence and type II diabetes, also leads
to loss of viability of PaCa cells (59.92%). Furthermore,
rolipram, which is under phase II clinical trial as an anti-
inflammatory drug, reduces cell viability (45.86%) by inhi-
biting phosphodiesterase 4D (PDE4D; STITCH score =
0.997 and IC50 = 31.6 nM). As these are approved drugs
(loperamide and yohimbine) and in clinical trials (roli-
pram), they are prime candidates for further study as po-
tential new pancreatic cancer drugs.
To evaluate the dosage dependence of the effect of our
small molecule inhibitors (eight PaCa inhibitors and two
non-PaCa inhibitors) on PaCa cell survival, we measured
cell viability using different small molecule concentrations.
We found that more than half of PaCa inhibitors reduced
cell viability in the low micromolar range. Of eight PaCa
inhibitors, five reduced cell viability in a dose-dependent
manner (Additional file 20; dasatinib, BMS-536924, A-
205804, rolipram and loperamide). Dasatinib, which
has been studied as a drug for pancreatic cancer treat-
ment [81], reduced cell viability to 50% at a concentra-
tion of 0.063 μM. Other PaCa inhibitors, BMS-536924,
A-205804, rolipram and loperamide, reduced cell viability
to 70% or less at concentrations ranging from 0.5 μM to
2.5 μM. In particular, we found that two repositioned
drugs, rolipram and loperamide, reduced cell viability to
50% at a concentration of around 5 μM. Meanwhile, the
negative controls, two non-PaCa inhibitors (D-4476 and
2-hydroxysaclofen) did not affect PaCa cell viability. On
average, they resulted in cell viability of 98.07% regardless
of their concentration. Taken together, these results sug-
gest that a portion of our predicted targets (five of eight in
these validations) show dose-dependent effects upon in-
hibition, thereby offering further experimental validation
of our approach. As no prediction is perfect, three of our
eight predicted PaCa small molecule inhibitors did not
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negative controls did either.
As a complementary approach to validate our pre-
dicted small molecule targets, we analyzed available high-
throughput drug screening data that were compiled in
CancerDR [67]. We examined IC50 values against 1,054
various types of cancer cell lines (including 51 BrCa, 37
PaCa and 18 OvCa cell lines that have been used to test
more than three inhibitors of our predicted targets) after
treating with 148 small molecules, including 39 known
inhibitors of our predicted targets. The inhibitors of our
predicted targets showed inhibitory activities at lower con-
centrations compared to the inhibitors of non-targets in
the given cancer types (Additional file 21). Inhibitors of
BrCa targets showed lower IC50 values in 41 BrCa cell
lines (80.39% of tested BrCa cell lines). Similarly, inhibitors
of PaCa targets (30 out of 37 cell lines) and OvCa targets
(18 out of 18 cell lines) showed better performance. Fur-
thermore, we found that inhibition efficiencies of cancer
target inhibitors are stronger in the given cancer com-
pared with other cancer types (Additional file 22). For ex-
ample, the IC50 value of PaCa target inhibitors is 25.45 μm
in PaCa cell lines, 2.81 times stronger than in other cancer
cells (71.48 μm). Inhibitors of BrCa targets and OvCa
targets also showed stronger effects in given cancer cell
lines. These results suggest that our predicted cancer
drug targets have functional relevance in cancer patho-
genesis and thus would be appropriate candidates for
anti-cancer therapeutics design.
Discussion
In this study, we demonstrate the importance of large-
scale data integration in identifying novel anti-cancer
drug targets. While there have been previous attempts
to predict drug targets, they have been limited due to a
lack of diversity of their datasets. Our results emphasize
the strong individual roles of gene essentiality, mRNA
expression, somatic mutation, DNA copy number and
network centrality to determine anti-cancer drug targets.
Indeed, we found that potential cancer drug targets are
likely to be essential, over-expressed, amplified and fre-
quently mutated in the given cancer types and have cru-
cial roles to maintain the PPI network. It suggests that
effective integration of genomic and systemic uniqueness
of drug targets captured dynamic regulation properties
of cancer drug targets, leading to the improved predic-
tion. Identification and validation of novel drug targets
is of course a lengthy and difficult procedure; we believe
that our work is helpful to give an initial prioritization of
proteins.
In addition to five major biological properties that we
used as features for cancer drug target identification, sev-
eral biological properties that are related to gene expression/
function regulation and genome evolution would be appliedas features to identify potential drug targets. It has been
shown that SNPs that affect rheumatoid arthritis-related
pathways are enriched in drug targets that are known to
be used for the treatment of rheumatoid arthritis [82].
Also, systematic mapping of tumor-specific transcriptional
networks and identification of negative genetic interac-
tions have been applied as a feature to identify therapeutic
targets for cancer [66,83]. Though these features have
been applied for drug target identification, their relatively
low coverage, due to low-throughput screening and/or
low coverage of the human genome, limits their usefulness
for genome-wide identification of drug targets. In the fu-
ture, when genome-wide data on those features are avail-
able, we expect that we can include them in our predictor
and provide more accurate and reliable target information.
Inhibitory strategies that can ultimately lead to the de-
velopment of new therapeutics are of crucial importance.
We thus present an integrated approach that shows three
different inhibitory strategies for the predicted cancer drug
targets: using antibodies, synthetic peptides and small
molecules (Figure 4). We thus show a direct route to val-
idate these targets in further experiments. We did so in a
few initial experiments to demonstrate the validity of our
approach. To this end, we performed high-throughput
chemical compound screening to evaluate the validity
of our results under more physiological conditions and
found several compounds that reduce cell viability by inhi-
biting our predicted targets (Figure 5; Additional file 16).
Of course, these are only preliminary validations and more
experiments are needed to establish our predictions as
bona fide novel targets. As well as repositioned drugs, we
suggest that the discussed small molecule inhibitors have
potential applications for cancer therapeutics. For ex-
ample, treatment with A-205804 (E-selectin (SELE) inhibi-
tor) and ACDPP hydrochloride (metabotropic glutamate
receptor 5 (GRM5) inhibitor) resulted in drastic reduction
of the viability of Panc0813 cells (66% cell viability;
Figure 5C). It has been suggested that down-regulation of
SELE and GRM5 significantly reduces cancer metastasis
[84] and cancer tumorigenesis [85]. Even if further chem-
ical optimizations of A-205804 and ACDPP hydrochloride
are required to improve efficacy and specificity, these re-
sults imply possible applications of these inhibitors for fur-
ther development against pancreatic cancer. Furthermore,
we identified 92 novel inhibitor candidates of PaCa targets
that resulted in reduced cell viability (cell viability <70%;
Additional file 23).
One particular promising venue to obtain novel ther-
apies is by repositioning existing drugs, as many of the
pitfalls of classical drug development can be sidestepped
this way. Indeed, we compiled a list of existing approved
drugs that inhibit some of our predicted targets. Interest-
ingly, we found that some repositioned drugs have clinical
indications related to cancer. For instance, yohimbine,
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ment for type II diabetes, has been investigated for its abil-
ity to induce apoptosis and inhibit cell proliferation of
pancreatic cancer cells [86]. It has been suggested that in-
hibition of ADRA2A alters the p21ras-mitogen-activated
protein (MAP) kinase cascade via a Gi-mediated pathway
and leads to apoptosis of cancer cells [87]. Interestingly, it
has been shown that cancer development is correlated
with the development of type II diabetes by the common
alteration of the insulin-like growth factor 1 receptor sig-
naling pathway, which is sensitive to insulin resistance and
affects growth and differentiation of cancer cells [88]. Roli-
pram, which is an anti-inflammatory drug and inhibits
PDE4D, has been shown to alter cell cycle progression,
leading to apoptosis of leukemia cells [89]. It has been
shown that inhibition of PDE4D enhances intracellular
cAMP, which controls several inflammatory cell functions
[90], and increased levels of cAMP induce apoptosis and
cell cycle arrest in cancer cells [91]. Also, several studies
have found that anti-inflammatory drugs exert their anti-
inflammatory and anti-tumor effects through the inhib-
ition of the cyclooxygenase-2 (COX-2) signaling pathway
[92]. These results imply that treatments using reposi-
tioned drugs can modify metabolic flux and signaling
pathways affecting the common pathophysiologic mecha-
nisms underlying cancer and consequently alter cancer
growth and proliferation.
Ultimately, our integrated approach generates a number
of promising leads for novel cancer therapies, which are
now straightforward to follow-up on. The obvious next
steps are to perform similar analyses focusing on genetic-
ally (rather than histologically) defined cancer subtypes.
Recently, several studies performed meta-analyses of can-
cer signatures (for example, somatic mutations and copy
number changes) with thousands of tumors and suggested
shared and cancer type-specific oncogenic properties
[10,93]. Such oncogenic signatures could be incorporated
into our predictor for the reliable prediction of cancer
subtype-specific drug targets. In future studies, two or
more of our predicted cancer drug targets, as well as exist-
ing drug targets, could be exploited using combinatorial
drug therapy by blocking different signaling pathways and
preventing cross-talk between pathways in cancer. Cor-
rectly predicting possible synergistic effects between two
or more drugs will be an exciting venue for future studies.
Conclusion
An ongoing challenge of cancer research is to prioritize
the selection of cancer drug targets, as is evident by the
slow development of novel anti-cancer agents. We devel-
oped a computational model to identify and validate
novel anti-cancer drug targets on a genome-wide scale.
We generated peptide inhibitors to high-scoring targets
using phage display and validate a subset of our noveldrug targets by showing efficacy of their inhibitors in
cancer cell lines. Furthermore, we carried out high-
throughput chemical library screens showing novel ef-
fects of known inhibitory small molecule compounds.
Beyond the three types of cancers we analyzed, there are
many other types of diseases for which various genomic
and systematic datasets are available. We believe that
the application of our integrated approach has the poten-
tial to provide a list of drug target candidates for other
human diseases.Additional files
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